As the epidermal growth factor receptor (EGFR) is a subject of common oncogenic alterations in GBM, we tested anti-EGFR therapy combined with temozolomide (first-choice medication for GBM) or with doxorubicin (common therapeutic for various solid and blood cancers). This evidence concerns the gene EGFR and glioblastoma.